Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | PolyPid Ltd.: PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025 | 1 | GlobeNewswire (USA) | ||
POLYPID Aktie jetzt für 0€ handeln | |||||
15.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 13 | SEC Filings | ||
15.07. | PolyPid stellt Plattform für 60-tägige GLP-1-Wirkstofffreisetzung vor | 1 | Investing.com Deutsch | ||
15.07. | PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment | 3 | Investing.com | ||
25.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
17.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
17.06. | PolyPid stock price target lowered to $14 at JMP on warrant dilution | 3 | Investing.com | ||
17.06. | PolyPid Ltd.: PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results | 1 | GlobeNewswire (USA) | ||
10.06. | PolyPid reports positive phase 3 surgical infection drug trial | 2 | Globes | ||
09.06. | Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial | 1 | Benzinga.com | ||
09.06. | PolyPid shares surge on successful D-PLEX100 trial results | 1 | Investing.com | ||
09.06. | PolyPid Ltd.: PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints | 238 | GlobeNewswire (Europe) | D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (pThe trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the... ► Artikel lesen | |
09.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
02.06. | H.C. Wainwright nimmt Beobachtung der PolyPid-Aktie mit Kaufempfehlung auf | 3 | Investing.com Deutsch | ||
30.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
29.05. | PolyPid bei Lytham Partners: Strategische Fortschritte und finanzielle Stabilität | 3 | Investing.com Deutsch | ||
21.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
14.05. | PolyPid GAAP EPS of -$0.70 beats by $0.12 | 1 | Seeking Alpha | ||
14.05. | PolyPid Ltd. Q1 Loss Beats Estimates | - | RTTNews | ||
14.05. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,50 | 0,00 % | BioNTech SE: Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union | Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu auftretende... ► Artikel lesen | |
EVOTEC | 7,378 | -0,30 % | Evotec-Aktie: Waren das wirklich schlechte Nachrichten? | Die Evotec-Aktie kam nach der Prognosesenkung am 21. Juli total unter die Räder und verlor zweistellig. Am Mittwoch erholt sie sich leicht und steht aktuell bei rund 6,30 €. Wie sind die neuen Zahlen... ► Artikel lesen | |
CUREVAC | 4,748 | +1,50 % | CureVac ÜBERRASCHT Anleger: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
AMGEN | 262,25 | -0,17 % | Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? | ||
DEFENCE THERAPEUTICS | 0,387 | +3,48 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,439 | -2,01 % | Breaking News: ExoPTEN von NurExone auf der Weltbühne! | ||
ABIVAX | 61,10 | +1,66 % | Abivax: Phase 3 Erfolg bei Therapie für Colitis ulcerosa - Aktienkurs explodiert | Abivax hat mit seinem Wirkstoff Obefazimod in zwei globalen Phase 3 Induktionsstudien bedeutende Fortschritte bei der Behandlung von moderat bis schwer aktiver Colitis ulcerosa erzielt. Das französische... ► Artikel lesen | |
IBIO | 0,660 | +10,92 % | XFRA DIVERSE ISINS: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
ARROWHEAD PHARMACEUTICALS | 13,635 | -1,05 % | Arrowhead says beleaguered Sarepta has 60 days to pay $100M in milestone | ||
COHERUS ONCOLOGY | 0,850 | -3,28 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
VOYAGER THERAPEUTICS | 3,058 | +10,56 % | Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach | - New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly-owned... ► Artikel lesen | |
OPGEN | 1,568 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
MEREO BIOPHARMA | 1,510 | +1,34 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis | NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled... ► Artikel lesen | |
APELLIS PHARMACEUTICALS | 16,032 | -2,32 % | Apellis Pharmaceuticals, Inc.: FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older | Proven efficacy across all three key markers of disease-68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents... ► Artikel lesen | |
BENITEC BIOPHARMA | 11,210 | +1,54 % | Benitec Biopharma Inc.: Benitec Biopharma Provides Operational Updates | -In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring... ► Artikel lesen |